-
1دورية أكاديمية
المؤلفون: Pascual Izquierdo, Cristina, Mingot Castellano, María Eva, Kerguelen Fuentes, Ana E., García-Arroba Peinado, José, Cid, Joan, Moraima Jimenez, Maria, Valcarcel, David, Gómez Seguí, Inés, de la Rubia, Javier, Martin, Paz, Goterris, Rosa, Hernández, Luis, Tallón, Inmaculada, Varea, Sara, Fernández, Marta, García Muñoz, Nadia, Vara, Míriam, Fernández Zarzoso, Miguel, García Candel, Faustino, Paciello, María Liz, García García, Irene, Zalba, Saioa, Campuzano, Verónica, Gala, José María, Vidán Estévez, Julia, Moreno Jiménez, Gemma, López Lorenzo, José Luis, González Arias, Elena, Freiría, Carmen, Solé, María, Ávila Idrovo, Laura Francisca, Hernández Castellet, José Carlos, Cruz, Naylen, Lavilla, Esperanza, Pérez Montaña, Albert, Atucha, Jon Ander, Moreno Beltrán, María Esperanza, Moreno Macías, Juán Ramón, Salinas, Ramón, del Rio Garma, Julio
المصدر: Blood Advances. Vol. 6, nº 24, December 2022, pp. 6219 - 6227
مصطلحات موضوعية: caplacizumab, prednisone, rituximab
الوصف: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P < .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P < .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX. ; 9 páginas
وصف الملف: application/pdf
-
2دورية أكاديمية
المؤلفون: Pascual Izquierdo, Cristina, Mingot Castellano, María Eva, Kerguelen Fuentes, Ana E., García Arroba Peinado, José, Cid Vidal, Joan, Jimenez, Maria Moraima, Valcarcel, David, Gómez Seguí, Inés, Rubia, Javier de la, Martin, Paz, Goterris, Rosa, Hernández, Luis, Tallón, Inmaculada, Varea, Sara, Fernández, Marta, García Muñoz, Nadia, Vara, Míriam, Fernández Zarzoso, Miguel, García Candel, Faustino, Paciello, María Liz, García García, Irene, Zalba, Saioa, Campuzano, Verónica, Gala, José María, Vidán Estévez, Julia, Moreno Jiménez, Gemma, López Lorenzo, José Luis, González Arias, Elena, Freiría, Carmen, Solé, María, Ávila Idrovo, Laura Francisca, Hernández Castellet, José Carlos, Cruz, Naylen, Lavilla, Esperanza, Pérez Montaña, Albert, Atucha, Jon Ander, Moreno Beltrán, María Esperanza, Moreno Macías, Juán Ramón, Salinas, Ramón, Rio Garma, Julio del, Spanish Apheresis Group (GEA), Spanish Thrombotic Thrombocytopenic Purpura Registry (REPTT)
المصدر: Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
مصطلحات موضوعية: Rituximab, Trombosi, Assaigs clínics, Thrombosis, Clinical trials
الوصف: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P < .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P < .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX.
وصف الملف: 9 p.; application/pdf
العلاقة: Reproducció del document publicat a: https://doi.org/10.1182/bloodadvances.2022008028Test; Blood Advances, 2022, vol. 6, num. 24, p. 6219-6227; https://doi.org/10.1182/bloodadvances.2022008028Test; http://hdl.handle.net/2445/196688Test
-
3دورية أكاديمية
المؤلفون: Pascual, Cristina, Mingot-Castellano, MarÃa Eva, Kerguelen Fuentes, Ana E., GarcÃa-Arroba, José, Cid, Joan, Jimenez, Moraima, Valcárcel, David, Gómez-SeguÃ, Inés, de la Rubia, Javier, Martin, Paz, Goterris, Rosa, Hernández, Luis, Tallón, Inmaculada, Varea, Sara, Fernández, Marta, GarcÃa-Muñoz, Nadia, Vara, MÃriam, Fernández-Zarzoso, Miguel, GarcÃa-Candel, Faustino, Paciello, MarÃa Liz, GarcÃa-GarcÃa, Irene, Zalba, Saioa, Campuzano, Verónica, Gala, José MarÃa, Vidan, Julia, Moreno-Jiménez, Gemma, López Lorenzo, José Luis, González Arias, Elena, FreirÃa, Carmen, Solé, MarÃa, Ãvila Idrovo, Laura Francisca, Hernández Castellet, José Carlos, Cruz, Naylen, Lavilla, Esperanza, Pérez-Montaña, Albert, Atucha, Jon Ander, Moreno Beltrán, MarÃa Esperanza, Moreno MacÃas, Juan Ramón, Salinas, Ramón, del Rio-Garma, Julio
الوصف: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P <.05) and less refractoriness (4.5% vs 14.1%; P <.05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P <.05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P <.001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX.
وصف الملف: application/pdf
العلاقة: Blood advances; Vol. 6 Núm. 24 (December 2022), p. 6219-6227; https://ddd.uab.cat/record/282297Test; urn:10.1182/bloodadvances.2022008028; urn:oai:ddd.uab.cat:282297; urn:scopus_id:85141669213; urn:articleid:24739537v6n24p6219; urn:pmid:35930694; urn:pmc-uid:9792393; urn:pmcid:PMC9792393; urn:oai:pubmedcentral.nih.gov:9792393
-
4دورية أكاديمية
المؤلفون: Zanabili Al-Sibai, Joud, Ávila Idrovo, Laura Francisca, Alonso Álvarez, Sara, Higueras Mora, Eduardo, Shehadeh Mahmalat, Sana
المصدر: Revista de la Facultad de Ciencias Médicas de Córdoba; Vol. 74 Núm. 3 (2017); 293-295 ; Revista da Faculdade de Ciências Médicas de Córdoba; v. 74 n. 3 (2017); 293-295 ; 1853-0605 ; 0014-6722 ; 10.31053/1853.0605.v74.n3
مصطلحات موضوعية: Mieloma Múltiple, Hibridación Fluorescente In Situ, Derrame Pleura
الوصف: El mieloma múltiple (MM) puede afectar al tórax en forma de lesiones óseas, plasmocitomas, infiltraciones pulmonares y derrame pleural. El derrame pleural por infiltración de células plasmáticas es poco frecuente, con una incidencia del 0,8% y menos de 100 casos descritos hasta la fecha.Presentamos el caso de un varón de 60 años que se le diagnosticó de mieloma múltiple. Tras recibir tratamiento y alcanzando remisión completa, se constata recaída precoz en forma de derrame pleural. Mostramos imágenes radiológicas, citológicas y de la traslocación t(14;16) por FISH. Se ha reportado que esta traslocación denota mal pronóstico, una clínica más agresiva y, a diferencia de otros subgrupos moleculares, su resultado no mejora con la introducción de bortezomib.
وصف الملف: application/pdf; application/vnd.openxmlformats-officedocument.wordprocessingml.document; image/jpeg
العلاقة: https://revistas.unc.edu.ar/index.php/med/article/view/16895/19378Test; https://revistas.unc.edu.ar/index.php/med/article/view/16895/26466Test; https://revistas.unc.edu.ar/index.php/med/article/view/16895/26467Test; https://revistas.unc.edu.ar/index.php/med/article/view/16895/26468Test; https://revistas.unc.edu.ar/index.php/med/article/view/16895/26469Test; https://revistas.unc.edu.ar/index.php/med/article/view/16895/26470Test; https://revistas.unc.edu.ar/index.php/med/article/view/16895/26471Test; https://revistas.unc.edu.ar/index.php/med/article/view/16895Test
-
5دورية
المؤلفون: Izquierdo, Cristina Pascual, Mingot-Castellano, María Eva, Fuentes, Ana E. Kerguelen, García-Arroba Peinado, José, Cid, Joan, Jimenez, Maria Moraima, Valcarcel, David, Gómez-Seguí, Inés, de la Rubia, Javier, Martin, Paz, Goterris, Rosa, Hernández, Luis, Tallón, Inmaculada, Varea, Sara, Fernández, Marta, García-Muñoz, Nadia, Vara, Míriam, Zarzoso, Miguel Fernández, García-Candel, Faustino, Paciello, María Liz, García-García, Irene, Zalba, Saioa, Campuzano, Verónica, Gala, José María, Estévez, Julia Vidán, Jiménez, Gemma Moreno, López Lorenzo, José Luis, Arias, Elena González, Freiría, Carmen, Solé, María, Ávila Idrovo, Laura Francisca, Hernández Castellet, José Carlos, Cruz, Naylen, Lavilla, Esperanza, Pérez-Montaña, Albert, Atucha, Jon Ander, Moreno Beltrán, María Esperanza, Moreno Macías, Juán Ramón, Salinas, Ramón, del Rio-Garma, Julio
المصدر: Blood Advances; December 2022, Vol. 6 Issue: 24 p6219-6227, 9p
مستخلص: Immune thrombotic thrombocytopenic purpura (iTTP) is a thrombotic microangiopathy caused by anti-ADAMTS13 antibodies. Caplacizumab is approved for adults with an acute episode of iTTP in conjunction with plasma exchange (PEX) and immunosuppression. The objective of this study was to analyze and compare the safety and efficacy of caplacizumab vs the standard of care and assess the effect of the concomitant use of rituximab. A retrospective study from the Spanish TTP Registry of patients treated with caplacizumab vs those who did not receive it was conducted. A total of 155 patients with iTTP (77 caplacizumab, 78 no caplacizumab) were included. Patients initially treated with caplacizumab had fewer exacerbations (4.5% vs 20.5%; P < .05) and less refractoriness (4.5% vs 14.1%; P < .05) than those who were not treated. Time to clinical response was shorter when caplacizumab was used as initial treatment vs caplacizumab used after refractoriness or exacerbation. The multivariate analysis showed that its use in the first 3 days after PEX was associated with a lower number of PEX (odds ratio, 7.5; CI, 2.3-12.7; P < .05) and days of hospitalization (odds ratio, 11.2; CI, 5.6-16.9; P < .001) compared with standard therapy. There was no difference in time to clinical remission in patients treated with caplacizumab compared with the use of rituximab. No severe adverse event was described in the caplacizumab group. In summary, caplacizumab reduced exacerbations and refractoriness compared with standard of care regimens. When administered within the first 3 days after PEX, it also provided a faster clinical response, reducing hospitalization time and the need for PEX.
-
6رسالة جامعية
المؤلفون: Armijos Torres, Jessica Cristina, Avila Idrovo, Laura Francisca, Bustamante Toledo, Juan Carlos
المساهمون: Mosquera Barzallo, Carlos Edmundo, Morales Sanmartín, Jaime Rodrigo
مصطلحات موضوعية: Prevalencia, Adolescente, Anemia Ferropenica, Menstruacion, Estudiantes, Menarquia
الوصف: Objetivos: Determinar la frecuencia de Anemia Ferropénica en estudiantes del sexo femenino del colegio Herlinda Toral de la ciudad de Cuenca, entre las edades entre los 12 a 18 años de edad. Métodos y materiales: Se realizó un estudio epidemiológico de prevalencia de tipo descriptivo y transversal, para la selección de la muestra se utilizo el programa Epi Info, Epidat, obteniéndose como resultado al azar 375 estudiantes. Se evaluaron: edad, menstruación, ciclo menstrual, días de sangrado, volumen de sangrado, hematíes, Hematocrito, Volumen corpuscular medio, Hemoglobina corpuscular media. Para definir los casos de anemia ferropénica se usaron los valores de hemoglobina, Hierro sérico, transferrina. También se examinó la asociación de éstas variables entre grupos de edad y menstruación. Resultados: La prevalencia de anemia ferropénica es de 4,8% Se encontró una mayor prevalencia en estudiantes de edades de 14 a 17 años (77,7%). Además se demostró una asociación entre todas las anémicas que ya han iniciado su menstruación, de las cuales un 50% tienen ciclos cortos menstruales, un 22,22% un periodo de sangrado de más de 7 días, un 72,22% presentan un volumen de sangrado diario alto. Se encontraron 18 estudiantes con valores bajos de hemoglobina(<12 g/ml) y de hierro sérico (<60ug/dl.); en los demás parámetros enumerados se encontraron normales, demostrándose así que no siempre la microcitosis y la ferropenia son indicativos de anemia ferropénica. Conclusiones: Las prevalencias de anemia ferropénica y deficiencia de hierro encontrado en la población estudiada fueron bajas, observándose una relación directa con las alteraciones de la menstruación, por un volumen de sangrado diario alto, aumento en los días de sangrado, o mayor frecuencia en presentación, aumentando el riesgo de anemia en las mujeres a partir de la menarquia. ; Objectives: To determine the frequency of Ferropénica Anemia in students of the feminine sex of the school Herlinda Toral of the city of River basin, enters the ages between the 12 18 ...
وصف الملف: application/pdf
العلاقة: MED-1632; http://dspace.ucuenca.edu.ec/handle/123456789/4109Test